Patent Foramen Ovale Closure Devices Market Summary

• The PFO Closure Devices market is estimated at USD 0.58 billion in 2025 and is projected to reach USD 1.14 billion by 2034. Growth is anchored in the strengthening clinical evidence linking PFO closure to the prevention of recurrent cryptogenic stroke, expanding guideline support and regulatory approvals, and the steady shift toward minimally invasive transcatheter structural heart procedures.
• The global PFO Closure Devices market is growing at a CAGR of 7.8% during the forecast period from 2026 to 2034.
• By product type, the Amplatzer PFO Occluder segment dominated the PFO Closure Devices market with a 54% share in 2025.
• By device type, the double-disc occluders segment dominated the PFO Closure Devices market with an 88% share in 2025.
• By material, the nitinol segment dominated the PFO Closure Devices market with a 92% share in 2025.
• By end user, the hospitals segment dominated the PFO Closure Devices market with a 71% share in 2025.
• North America dominated the global PFO Closure Devices market revenue with a 45% share in 2025, representing the highest regional market share globally.

A patent foramen ovale (PFO) closure device is a catheter-delivered implant used to permanently seal the foramen ovale, a flap-like opening between the right and left atria that normally closes shortly after birth but remains open in roughly one in four adults. In selected patients, a persistent PFO can allow a blood clot to bypass the lungs and travel to the brain, a mechanism known as paradoxical embolism that is implicated in cryptogenic stroke. PFO closure devices are delivered percutaneously through the femoral vein under fluoroscopic and echocardiographic guidance, where a self-expanding occluder is positioned across the septum to close the defect and, over time, becomes covered by native tissue. The market is organized by product type, including the Amplatzer PFO Occluder, the Cardioform Septal Occluder, and other devices; by device type across double-disc occluders, single-disc occluders, and other designs; by material across nitinol, polymeric materials, and others; by end user across hospitals, cardiac catheterization centers, specialty cardiology clinics, and ambulatory surgical centers; and by geography. Driven by randomized trial evidence, growing guideline endorsement, improved patient selection, and the broader migration of structural heart interventions to minimally invasive approaches, PFO closure devices have become an established option in secondary stroke prevention.

PFO Closure Devices Market Key Growth Drivers

• Randomized trials, including RESPECT and REDUCE, have shown that PFO closure combined with medical therapy reduces recurrent ischemic stroke in selected patients, with REDUCE reporting a 77% relative risk reduction for the Gore device versus antiplatelet therapy alone.
• The global stroke burden is large and rising, with the World Stroke Organization estimating roughly 12 million new strokes each year, and a substantial share of ischemic strokes in younger patients remaining cryptogenic.
• Growing clinical and guideline acceptance, including the American Academy of Neurology practice advisory and SCAI guidance, is broadening referral pathways between neurology and interventional cardiology.
• Regulatory approvals and next-generation launches, such as the FDA approvals of the Amplatzer PFO Occluder (2016), the Gore Cardioform Septal Occluder (2018), and the Amplatzer Talisman PFO Occlusion System (2021), are expanding the available device options.
• Rising adoption of minimally invasive transcatheter procedures, with shorter recovery times and lower complication rates than surgical closure, is shifting volume to catheterization laboratories and outpatient settings.
• Improved screening and diagnostic imaging, including transthoracic and transesophageal echocardiography and transcranial Doppler, is increasing the detection of clinically relevant PFOs.
• The convergence of stronger clinical evidence, stroke burden, guideline support, and device innovation is expected to sustain steady growth in the market through 2034.

Key Companies in PFO Closure Devices Market

The competitive landscape is led by the following active manufacturers:

• Abbott
• W. L. Gore & Associates, Inc.
• Occlutech Holding AG
• SMT
• Cardia Inc.
• Lepu Medical Technology (Beijing) Co., Ltd.
• Lifetech Scientific
• AGA Medical Corporation
• pfm medical ag
• Starway Medical Technology Inc.

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.

Patent Foramen Ovale (PFO) Closure Devices Market Size

The following snapshot summarizes the principal report metrics for the PFO Closure Devices market.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Patent Foramen Ovale (PFO) Closure Devices Market

Market Drivers

Strengthening Clinical Evidence and Guideline Support

The most powerful driver of the PFO Closure Devices market is the maturing clinical evidence base supporting transcatheter PFO closure for secondary stroke prevention. The RESPECT trial supported the first FDA approval of the Amplatzer PFO Occluder in October 2016, and the REDUCE trial, which showed a 77% relative reduction in recurrent ischemic stroke with the Gore Cardioform Septal Occluder plus antiplatelet therapy versus antiplatelet therapy alone, supported its April 2018 approval for the PFO indication. Later studies, including CLOSE and long-term follow-up of earlier trials, reinforced the benefit in patients with high-risk anatomical features such as an atrial septal aneurysm or a large shunt. These data have translated into practice recommendations from neurology and interventional cardiology bodies, which now support closure in carefully selected younger patients with cryptogenic stroke. As referral pathways between stroke neurologists and structural heart teams mature, procedure volumes and device demand rise, anchoring market growth through 2034.

Rising Burden of Ischemic and Cryptogenic Stroke

The growing global stroke burden is expanding the pool of patients who may be evaluated for PFO closure. The World Stroke Organization estimates roughly 12 million new strokes each year, and a significant proportion of ischemic strokes, particularly in patients under 60, have no identifiable cause after standard workup and are classified as cryptogenic. A PFO is present in about a quarter of adults, and in selected cryptogenic stroke patients it is considered a plausible embolic pathway. As awareness of the heart-brain connection grows and diagnostic work-ups become more systematic, a larger share of eligible patients is being identified and referred for closure, translating directly into sustained device demand across the forecast period.

Shift Toward Minimally Invasive Transcatheter Procedures

A structural shift toward minimally invasive therapy is a central growth engine for the market. Transcatheter PFO closure is performed through venous access, typically with conscious sedation or light anesthesia and imaging guidance, and patients commonly recover quickly and are discharged within a day. Compared with surgical closure, the transcatheter approach reduces procedural risk, hospital stay, and cost, which makes it the clear preferred option for patients, physicians, and payers. Improved delivery systems, such as pre-attached delivery cables and a broader range of device sizes, are simplifying procedures and shortening preparation time, further supporting adoption in high-volume centers and the expansion of the procedure into additional care settings through the forecast period.

Expanding Regulatory Approvals and Next-Generation Device Launches

A steady cadence of approvals and product iterations is increasing clinician choice and market penetration. The FDA approved the Amplatzer PFO Occluder in October 2016 and the Gore Cardioform Septal Occluder for PFO closure in April 2018, creating a two-supplier market in the United States. In September 2021, Abbott received FDA approval for the Amplatzer Talisman PFO Occlusion System and its delivery sheath, a next-generation system that comes pre-attached to its delivery cable and adds a 30 mm device size to treat a broader range of anatomies. Beyond the United States, devices from Occlutech, PFM Medical, Lifetech Scientific, Lepu Medical, Starway Medical, SMT, and Cardia broaden regional availability, while Occlutech is advancing the OCCLUFLEX study under an FDA investigational device exemption to pursue U.S. entry. Each approval and launch expands the addressable market and sustains competitive innovation.

Growing Diagnostic Detection and Procedure Capacity

Improved detection of clinically relevant PFOs and expanding procedural capacity are enlarging the treated population. Wider use of echocardiography with bubble studies, transesophageal echocardiography, and transcranial Doppler is helping stroke teams identify high-risk PFO features, while multidisciplinary PFO or stroke-heart teams are standardizing patient selection. At the same time, more cardiac catheterization centers and specialty cardiology clinics are building structural heart programs, increasing the number of operators able to perform closure. In emerging economies, rising cardiovascular investment and growing availability of locally manufactured occluders are making the procedure more accessible, contributing to a widening geographic footprint for PFO closure devices across the forecast period.

Stringent Regulatory and Quality Requirements Concentrating Demand

The demanding regulatory and clinical requirements of permanent cardiac implants are concentrating demand among established, evidence-backed manufacturers. Devices must satisfy premarket approval or equivalent pathways, support their claims with randomized or comparative clinical data, and maintain post-market surveillance for events such as device erosion, thrombus formation, and new-onset atrial fibrillation. Operators and hospitals tend to favor devices with long clinical track records, broad size ranges, and reliable delivery systems, which reinforces the positions of leading suppliers while raising barriers for new entrants. This dynamic sustains pricing and supports ongoing investment in clinical evidence and product refinement by incumbents across the forecast period.

Strategic Investment and Portfolio Expansion by Manufacturers

Manufacturer investment and portfolio activity are supporting the long-term growth of the market. The Amplatzer technology originated with AGA Medical, which St. Jude Medical acquired in 2010 before Abbott acquired St. Jude, giving Abbott a leading position in septal occluders. Gore has built a structural heart franchise around the Cardioform platform for both atrial septal defect and PFO closure. In February 2026, Alkem MedTech was reported to be acquiring up to a 55% stake in Occlutech, underscoring investor interest in mid-sized septal occluder specialists. Regional manufacturers in China, India, and Europe are also scaling production and extending product lines, which increases competition, improves access, and supports adoption across the forecast period.

Market Restraints

Despite steady momentum, the PFO Closure Devices market faces material constraints. The clinical indication is narrow: approved devices are indicated for selected patients, typically adults aged 18 to 60 with a cryptogenic ischemic stroke and a PFO after other causes have been excluded, and the incidence of closure in the much larger population with PFO but no stroke remains limited. Patient selection can be complex and requires neurology and cardiology coordination, which slows referrals in centers without an established PFO program. Procedural risks, including new-onset atrial fibrillation, device-related thrombus, erosion, and residual shunt, as well as the need for long-term antithrombotic therapy, temper adoption. Reimbursement and coverage policies vary across countries and payers, and in several markets closure for migraine or other non-stroke indications is not approved. Competition from medical therapy and evolving guideline interpretations can slow procedure growth, while the small number of suppliers with strong clinical evidence limits competitive pricing flexibility in some regions. Together, these indication, safety, reimbursement, and workflow barriers temper the pace of growth, even as the underlying drivers of stroke burden, clinical evidence, and minimally invasive therapy remain firmly intact.

Patent Foramen Ovale (PFO) Closure Devices Market Segment Analysis

The Patent Foramen Ovale (PFO) Closure Devices Market is segmented by product type (amplatzer pfo occluder, cardioform septal occluder, and others), device type (double-disc occluders, single-disc occluders, other device designs), material (nitinol, polymeric materials, other materials), end user (hospitals, cardiac catheterization centers, specialty cardiology clinics, ambulatory surgical centers), and geography (North America, Europe, Asia-Pacific, Rest of the World).

By Product Type

Dominant Subsegment: Amplatzer PFO Occluder. 

The Amplatzer PFO Occluder segment accounted for 54% of the PFO Closure Devices market in 2025. The Amplatzer PFO Occluder, now supplied by Abbott following its acquisition of St. Jude Medical, which had acquired AGA Medical in 2010, was the first device approved by the FDA for PFO closure to reduce the risk of recurrent ischemic stroke in October 2016, supported by the RESPECT trial. Its long clinical track record, wide operator familiarity, established delivery systems, and the 2021 launch of the Amplatzer Talisman PFO Occlusion System, which is pre-attached to its delivery cable and adds a 30 mm size, sustain its leadership in high-volume centers. The Cardioform Septal Occluder from W. L. Gore & Associates, approved in April 2018 on the strength of the REDUCE trial, is the principal alternative and is valued for its low-profile design. The Others category, which includes devices from Occlutech, pfm medical, Lifetech Scientific, Lepu Medical, Starway Medical, SMT, and Cardia, is growing as regional manufacturers expand availability outside the United States. Nonetheless, the evidence base and installed experience behind the Amplatzer platform secure its leadership across the forecast period.

By Device Type

Dominant Subsegment: Double-Disc Occluders. 

The double-disc occluders segment accounted for 88% of the PFO Closure Devices market in 2025. Double-disc occluders, which place a left atrial disc and a right atrial disc connected by a central waist across the septum, are the established design for PFO closure and are used by the leading approved devices, including the Amplatzer and Cardioform families. The configuration provides stable anchoring against the septum primum and septum secundum, a well-characterized deployment technique, and the largest body of clinical evidence from randomized trials. Operators are familiar with the technique, and tissue overgrowth over the discs supports long-term closure. Single-disc occluders and other designs, including suture-mediated and novel low-profile concepts under clinical investigation, aim to reduce implanted material and address anatomical variants, but their evidence and availability remain limited. The strength of trial data and clinical familiarity keep double-disc devices dominant across the forecast period.

By Material

Dominant Subsegment: Nitinol. 

The nitinol segment accounted for 92% of the PFO Closure Devices market in 2025. Nitinol, a nickel-titanium shape-memory alloy, is the leading material because it allows occluders to be compressed into small delivery sheaths and to self-expand and conform to the septal anatomy once deployed. Its superelasticity, fatigue resistance, and biocompatibility have made it the framework of choice for the major septal occluders, which typically pair a nitinol wire frame or mesh with a polyester or expanded polytetrafluoroethylene covering that promotes tissue ingrowth. Polymeric materials, including bioabsorbable concepts intended to leave less permanent material in the heart, attract research interest but account for a small share given limited clinical validation. Concerns around nickel sensitivity continue to motivate material research, yet the performance record of nitinol secures its leadership across the forecast period.

By End User

Dominant Subsegment: Hospitals. 

The hospitals segment accounted for 71% of the PFO Closure Devices market in 2025. Hospitals are the leading end user because PFO closure is performed in hospital catheterization laboratories with multidisciplinary stroke, cardiology, and imaging teams, with access to transesophageal or intracardiac echocardiography and anesthesia support. Most patients are identified in hospital stroke units, where neurologists refer eligible patients to structural heart specialists, and hospitals hold the infrastructure, device purchasing contracts, and reimbursement pathways needed for implantable devices. Cardiac catheterization centers contribute a growing share of procedures as dedicated structural heart programs expand, while specialty cardiology clinics support pre-procedure evaluation and follow-up. Ambulatory surgical centers are an emerging site of care as same-day discharge becomes more common and reimbursement evolves. Nonetheless, the clinical complexity and integrated care pathway keep hospitals the dominant end user across the forecast period.

Patent Foramen Ovale (PFO) Closure Devices Market Region Analysis

Dominant Region: North America

North America accounted for 45% of the global PFO Closure Devices market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the early FDA approvals of the Amplatzer PFO Occluder and the Cardioform Septal Occluder, strong clinical evidence from U.S.-led trials, and well-developed stroke and structural heart care networks, particularly in the United States. High awareness of the PFO-stroke link, established neurology-cardiology referral pathways, and a large number of catheterization laboratories support high procedure volumes. The presence of the leading suppliers, Abbott and W. L. Gore & Associates, and the launch of next-generation systems such as the Amplatzer Talisman support continued adoption, while established reimbursement and clear regulatory pathways anchor the region's leadership across the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the PFO Closure Devices market. The region's elevated CAGR is driven by a large and aging population, rising stroke incidence, expanding cardiovascular care infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Domestic manufacturers such as Lifetech Scientific, Lepu Medical, Starway Medical, and SMT are scaling production of locally developed occluders at competitive prices, improving access in cost-sensitive markets. Rising awareness of PFO-related stroke, growing numbers of trained structural heart operators, and regulatory pathways that increasingly recognize PFO closure are accelerating adoption. The combination of high disease burden, local manufacturing, and expanding access positions Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 45% of the global PFO Closure Devices market revenue in 2025. The United States dominates on the strength of early FDA approvals, strong trial evidence, established stroke networks, and the presence of Abbott and W. L. Gore & Associates, while next-generation launches and growing structural heart capacity reinforce its leadership.

Europe

Europe is a large and advanced regional market, supported by early CE-marked device availability, a strong tradition of structural heart intervention, and established regulatory frameworks. European manufacturers such as Occlutech and pfm medical complement the global suppliers, and adoption is supported by growing guideline endorsement across Germany, France, the United Kingdom, Italy, and Spain.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by rising stroke incidence, expanding cardiovascular infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. Local manufacturers, including Lifetech Scientific, Lepu Medical, Starway Medical, and SMT, are broadening device availability and accelerating regional market growth.

Rest of World

The Rest of the World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding cardiac care infrastructure, rising awareness of stroke prevention, and gradual improvement in access to transcatheter structural heart procedures are broadening adoption, while international distribution partnerships support the build-out of regional capacity.

Patent Foramen Ovale (PFO) Closure Devices Market Competitive Landscape

The PFO Closure Devices market is classified as Moderately Concentrated. A group of established global players with strong clinical evidence and broad regulatory approvals, led by Abbott, with the Amplatzer platform that originated with AGA Medical Corporation, and W. L. Gore & Associates, with the Cardioform Septal Occluder, anchors the top tier, while Occlutech Holding AG, pfm medical ag, Lifetech Scientific, Lepu Medical Technology (Beijing) Co., Ltd., Starway Medical Technology Inc., SMT, and Cardia Inc. compete through regional approvals, competitive pricing, and differentiated device designs, increasing competition in cost-sensitive and emerging markets.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with Abbott and Gore leading in the United States and a broader group of European and Asian manufacturers competing regionally.
• Leading players: Abbott and W. L. Gore & Associates anchor the top tier through proven clinical evidence from the RESPECT and REDUCE trials and wide operator familiarity.
• Geographic reach: Global leaders operate worldwide sales and clinical-support networks, while Occlutech, PFM Medical, Lifetech Scientific, Lepu Medical, Starway Medical, and SMT focus on Europe, China, India, and other emerging markets.
• Product portfolio strength: Leaders offer broad septal occluder families, multiple device sizes, and dedicated delivery systems, such as the Amplatzer Talisman system with a pre-attached delivery cable.
• Clinical evidence: Randomized trial data and long-term follow-up are a decisive competitive advantage in a market where selected-patient indications and guidelines drive adoption.
• Strategic partnerships: Investment and distribution partnerships, including Alkem MedTech's reported agreement to acquire up to a 55% stake in Occlutech, extend manufacturing and commercial reach.
• M&A activity: Consolidation history includes St. Jude Medical's 2010 acquisition of AGA Medical Corporation and Abbott's later acquisition of St. Jude Medical, which together built Abbott's septal occluder franchise.
• Manufacturing capabilities: Precision nitinol braiding, fabric and polymer covering, sterilization, and quality systems for permanent cardiac implants are key competitive moats.
• Innovation focus: Next-generation delivery systems, low-profile and single-disc concepts, suture-mediated closure, and improved biocompatible and bioabsorbable materials.

Patent Foramen Ovale (PFO) Closure Devices Market Recent Developmental Activities

In February 2026, Occlutech Holding AG was reported to have agreed to a strategic investment under which Alkem MedTech would acquire up to a 55% stake in the company. Strategic significance: Provides capital and commercial backing for a leading European septal occluder specialist and supports broader international expansion.

Patent Foramen Ovale (PFO) Closure Devices Market Segmentation

PFO Closure Devices Market by Product Type

• Amplatzer PFO Occluder
• Cardioform Septal Occluder
• Others

PFO Closure Devices Market by Device Type

• Double-Disc Occluders
• Single-Disc Occluders
• Other Device Designs

PFO Closure Devices Market by Material

• Nitinol
• Polymeric Materials
• Other Materials

PFO Closure Devices Market by End User

• Hospitals
• Cardiac Catheterization Centers
• Specialty Cardiology Clinics
• Ambulatory Surgical Centers

PFO Closure Devices Market by Geography

• North America PFO Closure Devices Market

• United States PFO Closure Devices Market Size in USD million (2023-2034)
• Canada PFO Closure Devices Market Size in USD million (2023-2034)
• Mexico PFO Closure Devices Market Size in USD million (2023-2034)
• Europe PFO Closure Devices Market
• Germany PFO Closure Devices Market Size in USD million (2023-2034)
• United Kingdom PFO Closure Devices Market Size in USD million (2023-2034)
• France PFO Closure Devices Market Size in USD million (2023-2034)
• Italy PFO Closure Devices Market Size in USD million (2023-2034)
• Spain PFO Closure Devices Market Size in USD million (2023-2034)
• Rest of Europe PFO Closure Devices Market Size in USD million (2023-2034)
• Asia-Pacific PFO Closure Devices Market
• China PFO Closure Devices Market Size in USD million (2023-2034)
• Japan PFO Closure Devices Market Size in USD million (2023-2034)
• India PFO Closure Devices Market Size in USD million (2023-2034)
• Australia PFO Closure Devices Market Size in USD million (2023-2034)
• South Korea PFO Closure Devices Market Size in USD million (2023-2034)
• Rest of Asia-Pacific PFO Closure Devices Market Size in USD million (2023-2034)
• Rest of the World (RoW) PFO Closure Devices Market
• Middle East PFO Closure Devices Market Size in USD million (2023-2034)
• Africa PFO Closure Devices Market Size in USD million (2023-2034)
• South America PFO Closure Devices Market Size in USD million (2023-2034)

Patent Foramen Ovale (PFO) Closure Devices Market Recent Industry Trends and Milestones (2023-2026)

Patent Foramen Ovale (PFO) Closure Devices Market Startup Funding and Investment Trends

Investment in the PFO Closure Devices ecosystem has focused on next-generation septal occluders, clinical evidence generation, and regional manufacturing scale-up. The following companies illustrate recent funding and investment activity and technology focus.

Capital activity in the PFO closure space reflects confidence in the clinical case for stroke prevention and in regional manufacturers. Alkem MedTech was reported in February 2026 to be acquiring up to a 55% stake in Occlutech, a European specialist in septal occluders, while clinical-stage developers pursuing implant-light concepts such as suture-mediated closure continue to generate clinical data. Established suppliers including Abbott and W. L. Gore & Associates invest in clinical evidence and next-generation delivery systems, and Asian manufacturers including Lifetech Scientific, Lepu Medical, and Starway Medical continue to scale domestic production. Collectively, these investments signal conviction that clinical evidence, device refinement, and regional manufacturing capacity will define the next phase of competitive advantage in the global PFO Closure Devices market.

Key Takeaways from the PFO Closure Devices Market Report Study

• Market size analysis for the current PFO closure devices market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global PFO closure devices market.
• Various opportunities available for competitors in the PFO closure devices market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current PFO closure devices market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for PFO closure devices market growth in the future?

Target audience who can benefit from this PFO closure devices market report study 

• PFO closure devices manufacturers and product providers
• Research organizations and consulting companies
• PFO closure devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in PFO closure devices
• Various end-users who want to know more about the PFO closure devices market and the latest technological developments in the PFO closure devices market.